Defunct Company
Total Trials
8
As Lead Sponsor
6
As Collaborator
2
Total Enrollment
3,660
NCT01579383
Safety Tolerability and Pharmacokinetics of ALD403
Phase: Phase 1
Role: Lead Sponsor
Start: Apr 30, 2012
Completion: Apr 30, 2013
NCT01772524
Safety, Efficacy and Pharmacokinetics of ALD403
Start: Jan 31, 2013
Completion: Feb 28, 2014
NCT02275117
A Multicenter Assessment of ALD403 in Chronic Migraine
Phase: Phase 2
Start: Oct 31, 2014
Completion: Nov 30, 2016
NCT02559895
A Multicenter Assessment of ALD403 in Frequent Episodic Migraine
Phase: Phase 3
Start: Sep 30, 2015
Completion: Dec 31, 2017
NCT02974153
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
Start: Nov 30, 2016
Completion: Apr 30, 2018
NCT02985398
An Open Label Trial of ALD403 (Eptinezumab) in Chronic Migraine
Start: Dec 31, 2016
Completion: Mar 31, 2019
NCT04197349
Safety, Tolerability and Pharmacokinetics of ALD1910 in Healthy Men and Woman
Role: Collaborator
Start: Sep 24, 2019
Completion: Aug 19, 2020
NCT04152083
A Study to Evaluate the Efficacy and Safety of Eptinezumab Administered Intravenously in Participants Experiencing Acute Attack of Migraine
Start: Nov 7, 2019
Completion: Jul 8, 2020